Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Human Tissue Core (U01- Clinical Trial Not Allowed) - 0 views
-
MiamiOH OARS on 30 Jul 18The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D Molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale Molecular profiles associated with spatial information to provide Molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the Molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.